Urinary tract tumors, biology and risk for artificial sweeteners use with particular emphasis on some South American countries

Current Nutrition and Food Science

Volumn 4, Issue 3, 2008, Pages 185-195

  Andreatta, Mary M ^a   Navarro, Alicia ^a   Eynard, A R ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Artificial sweeteners; Experimental and epidemiological evidence; South America; Urinary tract tumors; Urothelium

Indexed keywords

ARSENIC; ASPARTAME; CYCLAMATE SODIUM; SACCHARIN SODIUM; SWEETENING AGENT;

BLADDER CARCINOGENESIS; BLADDER IRRITATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CORRELATION ANALYSIS; CYTOLOGY; DIETARY INTAKE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HEREDITY; HISTOPATHOLOGY; HUMAN; INFECTION; LONG TERM EXPOSURE; MOLECULAR MECHANICS; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOUTH AMERICA; TREND STUDY; URINARY TRACT TUMOR; UROTHELIUM;

EID: 55249118137     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340108785133338     Document Type: Review

References (120)

1. World Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. AICR 2007.
2. Iscovich J, Castelletto R, Esteve J, et al. Tobacco smoking, occupational exposure and bladder cancer in Argentina. Int J Cancer 1987; 40, 734-40.
3. Restrepo HE, Correa P, Haenszel W, Brinton LA, Franco A. A case-control study of tobacco-related cancers in Colombia. Bull Pan Am Health Organ 1989; 23: 405-13.
4. Laura EA, de Larminat S, Azcon P. Tumor regional registry of the southern Buenos Aires province. Data of the first biennial, 1989-1990. Medicina (B Aires) 1993; 53: 223-31.
5. Mattos IE, Koifman S. Cancer mortality among electricity utility workers in the state of Sao Paulo, Brazil. Rev Saude Publica 1996; 30: 564-75.
6. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996; 7: 117-24.
7. Gontijo AM, Elias FN, Salvadori DM, et al. Single-cell gel (comet) assay detects primary DNA damage in nonneoplastic urothelial cells of smokers and ex-smokers. Cancer Epidemiol Biomarkers Prev 2001; 10: 987-93.
8. Balbi JC, Larrinaga MT, De Stefani E, et al. Foods and risk of bladder cancer: a case-control study in Uruguay. Eur J Cancer Prev 2001; 10: 453-8.
9. Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 2004; 211: 199-207.
10. Bates M, Hopenhayn C, Rey OA, Moore LE. Bladder cancer and mate consumption in Argentina: A case-control study. Cancer Lett 2007; 246, 268-78.
11. De Stefani E, Boffetta P, Deneo-Pellegrini H, et al. Non-alcoholic beverages and risk of bladder cancer in Uruguay. BMC Cancer 2007; 7: 57.
12. Yuan Y, Marshall G, Ferreccio C, et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol 2007; 166: 1381-91.
13. International Agency for Research on Cancer. Eble JN, Sauter G, Epstein JI, Sestehenn IA, Eds. Pathology end Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press 2004; pp. 89-109.
14. Eynard AR. Is the risk of urinary tract tumorigenesis enhanced by a marginal chronic essential fatty acid deficiency (EFAD)? Nutrition 1998; 14: 235-7.
15. Apodaca G. The Uroepithelium: not just a passive barrier. Traffic 2004; 5: 117-128.
16. Actis AB, Joekes S, Cremonezzi, D Morales G, Eynard AR. Effects of dietary lipids on cell proliferation of murine oral mucosa. Lipids Health Dis 2002; 1: 1-4.
17. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 2000; 278: 867-74.
18. Monis B, Dorfman HS. Some hitochemical observations on transitional epithelium of man. J Histochem Cytochem 1967; 15: 475-481.
19. Monis B, Zambrano D. Ultraestructure of transitional epithelium of man. Z Zellforsch Mikrosk Anat 1968; 87: 101-117.
20. Monis B, Gomez A, Candiotti A, Ibañez N. The Tamm-Horsfall glycoprotein and the urinary system electrophoretic and electron microscopic observations. Life Sci 1972; 11: 699-708.
21. Eynard AR, Monis B. Concavalin A sites urothelium and milk fat globules of essential fatty acid (EFA) deficient rats. J Submicrosc Cytol 1983; 15: 375-82.
22. Higuchi T, Xin P, Buckley MS, Erickson DR, Bhavanandan VP. Characterization of the rabbit homolog of human MUC1 glycoprotein isolated from bladder by affinity chromatography on immobilized jacalin. Glycobiology 2000; 10: 659-67.
23. Calderon RO, Glocker M, Eynard AR. Lipid and fatty acid composition of different fractions from rat urinary transitional epithelium. Lipids 1998; 33: 1017-22.
24. Cohen SM. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 2002; 30: 663-71.
25. Romanenko AM. Ultrastructural diagnostic markers of the urinary bladder precancer. Bull Assoc Anat (Nancy) 1989; 73: 31-5.
26. Ohtsuka Y, Kawakami S, Fujii Y. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int 2006; 97: 1322-6.
27. Ketterer B, Hicks RM, Christodoulides L, Beale D. Studies on the chemistry of the luminal plasma membrane of rat bladder epithelium cells. Biochem Biophys Acta 1973; 311: 180-90.
28. Kalinec F, Calderón JH, Monis B. Ultrastructural variations of the urothelial membrane in essential fatty acid (EFA)-deficient rats. A digital densitometric study. J Histochem Cytochem 1986; 34: 1639-44.
29. Bongiovanni GA, Eynard AR, Calderón RO. Altered lipid profile and changes in uroplakin properties of rat urothelial plasma membrane with diets of different lipid composition. Mol Cell Biochem 2005; 271: 69-75.
30. Calderon RO, Grasso EJ. Symmetric array of the urothelium surface controlled by the lipid lattice composition. Biochem Biophys Res Commun 2006; 339: 642-6.
31. Monis B, Eynard AR. Incidence of urothelial tumours in rats deficient in essential fatty acids. J Natl Cancer Inst 1980; 64: 73.
32. Monis B, Eynard AR. Abnormal cell proliferation and differentiation and urothelial tumorigenesis in essential fatty acid deficient (EFAD) rats. Prog Lip Res 1981; 20: 691-703.
33. Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis 2008; 7: 9.
34. Eynard AR. Does chronic essential fatty acid deficiency constitute a pro-tumorigenic condition? Medical Hypotheses 1997; 48: 55-62.
35. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, Eds. Cancer Incidence in Five Continents. Vol VIII. IARC Scientific Publications no 155, Lyon, IARC 2003.
36. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48.
37. Lopez-Beltran A, Croghan GA, Croghan I, Matilla A, Gaeta JF. Prognostic factors in bladder cancer. A pathologic, inmunohistochemical and DNA flow-cytometric study. Am J Clin Pathol 1994; 102: 109-14.
38. Mostofi FK, Davis CJ, Sesterhenn IA. World Health Organization International Histological Classification of Tumours. Histological Typing of Urinary Bladder Tumours. 2nd ed. Berlin, Springer Verlag 1999.
39. Stewart BW et Kleihues P, Eds. Le Cancer dans le Monde. Lyon, IARC Press 2005; 232.
40. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol I to VIII. Lyon, IARC 2005.
41. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
42. International Agency for Research on Cancer. Globocan 2002. Lyon 2006; available at: http://www-dep.iarc.fr/
43. World Health Organization. Statistical Information System. Mortality Database. Numbers and rates of registered deaths. WHO, 2001. Avaliable at: http://www.who.int/whosis/database/mort/table1_process.cfm
44. Ministerio de Salud y Deporte de Bolivia. Situación de Salud. Bolivia 2004. Sistema Nacional de Información y Vigilancia Epidemiológica. Bolivia, Serie Documentos de Divulgación Científica 2006.
45. Silverman DT, Morrison AS, Devesa SS. Bladder Cancer. In: Cancer Epidemiology and Prevention. Schottenfeld D, Fraumeni JF Jr. Eds. 2nd Ed. New York, Oxford University Press 1996; 1156-1179.
46. La Vecchia C and Airoldi L. Human bladder cancer: epidemiological, pathological and mechanistic aspects. In: Species differences in thyroid, kidney and urinary bladder carcinogenesis (Eds. Capen CC, Dybing E, Rice JM, Wilboum JD). Lyon, ARC Scientific Publication No. 147; International Agency for Research on Cancer 1999; 139-157.
47. Negri E, La Vecchia C. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 2001; 10: 7-14.
48. International Agency for Research on Cancer. Cancer Incidence in Five Continents Vol. IX. Lyon 2007; available at: http://wwwdep.iarc.fr/
49. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 1998; 147: 660-9.
50. Bates MN, Rey OA, Biggs ML, et al. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am J Epidemiol 2004; 159: 381-9.
51. Marshall G, Ferreccio C, Yuan Y, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007; 99: 920-8.
52. Kramer AA, Graham S, Burnett WS, Masca P. Familial aggregation of bladder cancer stratified by smoking status. Epidemiology 1991; 2: 145-148.
53. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in firstdegrees relatives of cancer probands. J Natl Cancer Pathol 1994; 86: 1600-1608.
54. Kiemeney LA, Moret NC, Witjes JA, Schoenberg MP, Tulinuis H. Familial transitional cell carcinoma among the population of Iceland. J Urol 1997; 157: 1649-1651.
55. Plna C, Hemminki K. Familial bladder cancer in the national swedish family cancer database. J Urol 2001; 166: 2129-2133.
56. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002; 98: 274-278.
57. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 1998; 3: 81-85.
58. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677-685.
59. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results of the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-59.
60. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk to humans. Tobacco smoke and involuntary smoking. Lyon, IARC Press 2004.
61. Brennan P, Bogillot O, Cordier S, et al. Cigarette smoking and bladder cancer in men: a pool analysis of 11cae-control studies. Int J Cancer 2000; 86: 289-94.
62. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006; 3(6): 327-40.
63. Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smokingrelated bladder cancer risk. J Natl Cancer Inst 2001; 93: 538-45.
64. Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. Int J Cancer 2003; 105: 108-112.
65. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. Lyon, IARC Press 1987.
66. Tanguay C, Harvey I, Houde M, Srigley JR, Tetu B. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003; 16: 512-514.
67. Cremonezzi DC, Díaz MP, Valentich MA, Eynard AR. Neoplastic and preneoplastic lesions induced by melamine in rat urothelium are modulated by dietary polynsaturated fatty acids. Food Chem Toxicol 2004; 42: 1999-2007.
68. Cremonezzi DC, Silva RA, Díaz MP, Valentich MA, Eynard AR. Dietary PUFAs differentially modulate melamine-induced preneoplastic urothelial proliferation and apoptosis in mice. Prostgl Leuk Essent Fatty Acids 2001; 64: 151-159.
69. Bongiovanni GA, Soria EA, Eynard AR. Effects of the plant flavonoids silymarin and quercetin on arsenite-induced oxidative stress in CHO-K1 cells. Food Chem Toxicol 2007; 45: 971-976.
70. Soria EA, Eynard AR, Quiroga PL, Bongiovanni GA. Differential effects of quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines. Life Sci 2007; 81: 1397-1402.
71. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151: 693-702.
72. Nagano J, Kono S, Preston DL, et al. Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int J Cancer 2000; 86: 132-138.
73. Michaud DS, Pietinen P, Taylor PR, et al. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 2002; 87: 960-965.
74. Steineck G, Hagman U, Gerhardsson M, Norell SE. Vitamin A suplements, fried foods, fat and urotelial cancer. A case-reference study in Stockholm in 1985-87. Int J Cancer 1990; 15: 1006-11.
75. Tavani A, La Vecchia C. Coffee and cancer: a review of epidemiological studies. Eur J Cancer Prev 2000; 9: 241-256.
76. National Cancer Institute. Artificial Sweeteners and Cancer: Questions and Answers. USA, US National Institutes of Health 2008; available at: http://www.cancer.gov/cancertopics/factsheet/Risk/ artificial-sweeteners.
77. Suttajit M, Vinitketkaumnuen U, Meevatee U, Buddhasukh D. Mutagenicity and human chromosomal effect of stevioside, a sweetener from Stevia rebaudiana Bertoni. Environ Health Perspect 1993; 101: 53-6.
78. Yasukawa K, Kitanaka S, Seo S. Inhibitory effect of stevioside on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Biol Pharm Bull 2002; 25: 1488-90.
79. Douglas Kinghorn A. Stevia: The genus Stevia. Medicinal and Aromatic Plants - Industrial Profiles Series, London, Taylor & Francis 2002; 19: p 12.
80. Koyama E, Sakai N, Ohori Y, et al. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. Food Chem Toxicol 2003; 41: 875-83.
81. Weihrauch MR, Diehl V. Artificial sweeteners-do they bear a carcinogenic risk? Ann Oncol 2004; 15: 1460-5.
82. Mitchell ML, Pearson RL. Saccharine. In: O'Brien Nabors L and Geraldi RC, Eds. Alternative Sweeteners, 2nd Ed. New York, Marcel Dekker 1991; 127-156.
83. Beck KM. Sweeteners, non-nutritive. In: Encyclopedia of Chemical Technology (Kirk RE and Othmer DF) Eds. 2nd Ed, Vol. 19. New York, John Wiley and Sons 1969; 598-607.
84. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Some non-nutritive sweetening agents. IARC Working Group on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Lyon, IARC Press 1980; 62-3.
85. Sommer F, Klotz T, Schmitz-Dräger BJ. Lifestyle issues and genitourinary tumours. World J Urol 2004; 21: 402-13.
86. Ager DJ, Pantaleone DP, Henderson SA, Katritzky AR, Prakash I, Walters DE. Commercial, synthetic nonnutritive sweeteners. Ange Chem Int Ed Engl 1998; 37: 1802-1817.
87. Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L, Tibaldi E, Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environm Health Perpect 2006; 114: 379-385.
88. Andreatta MM, Muñoz SE, Lantieri MJ, Eynard AR, Navarro A. Artificial sweetener consumption and urinary tract tumors in cordoba, Argentina. Prev Med 2008; in press.
89. Toledo MC, Ioshi SH. Potential intake of intense sweeteners in Brazil. Food Addit Contam 1995; 12: 799-808.
90. Secretaría de Agricultura, Ganadería, Pesca y Alimentación de Argentina. Análisis de la Cadena de Edulcorantes. Dirección de Industria Alimentaria. Buenos Aires, 2000. Avaliable at: http://www.alimentosargentinos.gov.ar/0-3/azucar/ edulco/Edulcorantes.htm
91. Sewram V, De Stefani E, Brennan P, Boffetta P. Maté Consumption and the Risk of Squamous Cell Esophageal Cancer in Uruguay. Cancer Epidemiol Biomarkers Prev 2003; 12: 508-513.
92. Norman JT, Howlett AR, Spacey GD, Hodges GM. Effects of treatment with N-methyl-N-nitrosurea, artificial sweeteners, and cyclophosphamide on adult rat urinary bladder in vitro. Lab Invest 1987; 57: 429-38.
93. Kakizoe T, Nishio Y, Ohtani M, Niijima T, Sato S, Sugimura T. Correlation of results of agglutination assays with concanavalin A and carcinogenesis experiments on promoters of bladder cancer. Jpn J Cancer Res 1985; 76: 930-6.
94. Takayama S, Sieber SM, Adamson RH, et al. Long-term Feeding of Sodium Saccharin to Nonhuman Primates: Implications for Urinary Tract Cancer. J Natl Cancer Inst 1998; 90: 19-25.
95. Takayama S, Renwick AG, Johansson SL, et al. Long-term toxicity and carcinogenicity study of cyclamate in nonhuman primates. Toxicol Sci 2000; 53: 33-9.
96. Cohen SM. Promotion in urinary bladder carcinogenesis. Environ Health Perspect 1983; 50: 51-9.
97. Cohen SM, Arnold LL, Cano M, Ito M, Garland EM, Shaw RA. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis, 2000; 21: 783-792.
98. Cohen SM, Cano M, Garland EM, St. John M, Arnold LL. Urinary and urothelial effects of sodium salts in male rats. Carcinogenesis 1995; 16: 343-348.
99. Zurlo J, Squire RA. Is Saccharin Safe? Animal testing revisited. Natl Cancer Instit 1998; 90: 2-3.
100. Armstrong B, Doll R. Bladder cancer mortality in England and Wales in relation to cigarette smoking and saccharin consumption. Br J Prev Soc Med 1974; 28: 233-40.
101. Jensen OM, Kamby C. Intra-uterine exposure to saccharin and risk of bladder cancer in man. Int J Cancer 1982; 29: 507-9.
102. Morrison AS, Buring JE. Artificial sweeteners and cancer of the lower urinary tract. N Engl J Med 1980; 302: 537-41.
103. Wynder EL, Stellman SD. Artificial sweetener use and bladder cancer: a case-control study. Science 1980; 207: 1214-6.
104. Moller-Jensen O, Knudsen JB, Sorensen BL, Clemmesen J. Artificial sweeteners and absence of bladder cancer risk in Copenhagen. Int J Cancer 1983; 32: 577-82.
105. Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR. Dietary factors and the incidence of cancer of the urinary bladder. Am J Epidemiol 1988; 127: 1179-91.
106. Wakai K, Ohno Y, Obata K, Aoki K. Prognostic significance of selected lifestyle factors in urinary bladder cancer. Jpn J Cancer Res 1993; 84: 1223-9.
107. Howe GR, Burch JD, Miller AB, et al. Artificial sweeteners and human bladder cancer. Lancet 1977; 2: 578-81.
108. Sturgeon SR, Hartge P, Silverman DT, et al. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 1994; 5: 218-25.
109. Cartwright RA, Adib R, Glashan R, Gray BK. The epidemiology of bladder cancer in West Yorkshire. A preliminary report on nonoccupational etiologies. Carcinogenesis 1981; 4: 343-347.
110. Muñoz SE, Navarro A, Lantieri MJ, et al. Alcohol, mathylxantine beverages and colorectal cancer in córdoba, argentina. Eur J Cancer Prev 1998; 7: 207-13.
111. Navarro A, Osella AR, Muñoz SE, Lantieri MJ, Fabro EA, AR Eynard. "Fatty acids, fibres and colorectal cancer risk in Córdoba, Argentina". J Epidemiol Biostat 1998; 3: 415-422.
112. Navarro A, Díaz MP, Muñoz SE, Lantieri MJ, Eynard AR. Characterization of meat consumption and risk of colorectal cancer in córdoba, Argentina. Nutrition 2003; 19: 7-10.
113. Navarro A, Muñoz SE, Diaz MP, P de Fabro S, Cristaldo PE, Eynard AR. Meat cooking habits and risk of colorectal cancer in cordoba, argentina. Nutrition 2004; 20: 873-7.
114. Navarro A, Osella AR, Guerra V, Mu⊤noz SE, Lantieri MJ, Eynard AR. Reproducibility and validity of a food-frequency questionnaire in assessing dietary intakes and food habits in epidemiological cancer studies in argentina. J Exp Clin Cancer Res 2001; 20: 203-208.
115. Breslow NE, Day NE. Statistical methods in cancer resarch. Vol I. The analysis of case-control studies. Lyon, IARC, 1980; 32: 227-260.
116. Mc Cullagh P, Nelder JA. Binari data. In: Generalized linear models. London, editorial chapman and hall, 1989; 98-135.
117. World Health Organization. Evaluation of Certain Food Additives and Contaminants (WHO Technical Report Series 837). Geneva 1993.
118. Renwick AG. Intense sweeteners intake surveys: Methods, results and comparisons. In: Intake Studies-Lessons Learnt, ISA Symposium, Brussels, November 27, 1995. Brussels, International Sweeteners Association 1995.
119. International Agency for Research on Cancer. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances/IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Lyon, IARC Press 1999; 195-198, 517-523.
120. Lean ME, Hankey CR. Aspartame and its effects on health. Br Med J 2004; 329: 755-56.